ArticleBMC medical genomics2025
Identification of hub genes contributing to acute eczema using transcriptome sequencing and machine-learning approaches.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcute eczema (AE) is a multifactorial inflammatory skin disease with complex immune dysregulation. The identification of key pathogenic genes may provide novel biomarkers and therapeutic targets.
methodsAn AE rat model was induced using DNCB. Transcriptome sequencing was performed on skin lesions, and differentially expressed genes (DEGs) were identified via DESeq2. Weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) network construction, functional enrichment, and "Friends" analysis were applied to screen hub genes. Multiple machine learning algorithms, including LASSO, support vector machine (SVM), and random forest (RF), were integrated for candidate selection. Quantitative real-time PCR (qRT-PCR), Western blotting, and immunohistochemistry were used for validation.
resultsA total of 1717 DEGs (1190 upregulated, 527 downregulated) were identified. WGCNA and PPI analysis yielded 36 hub genes enriched in immune and inflammatory pathways, particularly Th1/Th2/Th17 differentiation, JAK-STAT, and PI3K-Akt signaling. Cross-validation by machine learning highlighted Icam1 as a top candidate. Experimental assays confirmed significant upregulation of ICAM-1 at mRNA and protein levels in AE lesions compared with controls.
conclusionIcam1 is a key gene potentially driving inflammatory infiltration in AE and may serve as a diagnostic target. This integrative bioinformatics-experimental approach provides a robust framework for discovering pathogenic genes in inflammatory skin diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.